Akebia TherapeuticsvsThermo Fisher Scientific

AKBA and TMO stock compared: price, dividend, valuation and results, from SEC filings.

AKBA

Akebia Therapeutics, Inc.

$0.45

Value $121M

-5.00%
AKBA's page

TMO

Thermo Fisher Scientific Inc

$692.08

Value $257B

-1.16%
TMO's page

Akebia Therapeutics (AKBA) has a market value of $121M and Thermo Fisher Scientific (TMO) $257B. Over the last year, with dividends, AKBA moved -73.0% and TMO +20.0%. Dividend yield: AKBA none, TMO 0.27%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AKBA$121M

    TMO$257B

    TMO is 2,131 times AKBA

  • Revenue, 12 months

    AKBA$197M

    TMO$47.4B

    TMO is 240 times AKBA

  • Net income, 12 months

    AKBA-$45M

    TMO$7.1B

  • Operating margin

    AKBA-15.7%

    TMO17.9%

    33.6 points apart

  • ROIC

    AKBA-31.3%

    TMO8.2%

    39.5 points apart

  • P/E

    AKBA–

    TMO36.4

  • Dividend yield

    AKBA0.0%

    TMO0.3%

    0.3 points apart

  • 5-year return

    AKBA-84.3%

    TMO+11.0%

    95.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AKBA-84.3%

TMO+11.0%

5010020222023202420252026
Returns by period
PeriodAKBAWith dividendsTMOWith dividends
1 year since November 14, 2025-73.0%Price -73.0%+20.0%Price +19.6%
3 years since November 16, 2023-54.5%-23.1% a yearPrice -54.5%+47.9%+13.9% a yearPrice +46.5%
5 years since November 15, 2021-84.3%-31.0% a yearPrice -84.3%+11.0%+2.1% a yearPrice +9.4%
10 years since November 16, 2016-94.9%-25.8% a yearPrice -94.9%+376.2%+16.9% a yearPrice +363.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AKBAAkebia TherapeuticsTMOThermo Fisher Scientific

Valuation

AKBATMO
Valuation
Price$0.45$692.08
Market value$121M$257B
Enterprise value (EV)$12M$292B
P/E–36.4
P/E, 5-year median–32.7
P/B5.94.7
EV/EBIT–34.5
Free cash flow yield11.5%2.9%

Results and growth

AKBATMO
Results and growth
Revenue, 12 months$197M$47.4B
Net income, 12 months-$45M$7.1B
Free cash flow, 12 months$14M$7.6B
Earnings per share, 12 months-$0.16$18.96
Revenue growth, year on year47.5%3.9%
Revenue growth a year, past-4.3%over 5 years+6.7%over 5 years
EPS growth a year, past–+2.1%over 5 years

Margins and returns on capital

AKBATMO
Margins and returns on capital
Gross margin78.9%–
Operating margin-15.7%17.9%
Net margin-22.6%14.9%
ROIC-31.3%8.2%
ROE-151.6%13.4%

Balance sheet

AKBATMO
Balance sheet
Cash$159M$6.1B
Total debt$60M$41.4B
Net debt / EBITDA–3.7
Interest cover–5.5×

Dividends and buybacks

AKBATMO
Dividends and buybacks
Dividend yield–0.3%
Dividend per share, 12 months–$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield–1.2%
Shareholder yield–1.4%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AKBA or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, Akebia Therapeutics or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($257B) is about 2,131.4 times Akebia Therapeutics ($121M), at today's prices.

How did AKBA and TMO stock do over the last 10 years?

Since November 16, 2016, AKBA's price moved -94.9% and TMO's +363.0%. With dividends: AKBA -94.9% (-25.8% a year), TMO +376.2% (+16.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, AKBA or TMO?

The dividend yield at today's price is none for Akebia Therapeutics and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.

Which has the higher profit margins, Akebia Therapeutics or Thermo Fisher Scientific?

Over the last twelve months, the net margin was -22.6% for Akebia Therapeutics and 14.9% for Thermo Fisher Scientific, and the operating margin -15.7% and 17.9%. Revenue was $197M and $47.4B.

Which is the better investment, Akebia Therapeutics or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.